Completed PHASE3 INTERVENTIONAL NCT00209300

Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission

Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission. A European Multi-centre Investigator Blinded Randomized Controlled Study of Pentasa Sachet Comparing One Gram Twice With Two Grams Once Daily

Sponsor: Ferring Pharmaceuticals

Conditions Ulcerative Colitis

Interventions Pentasa

Updated 6 times since 2017 Last updated: May 18, 2011 Started: May 31, 2005 Primary completion: May 31, 2007 Completion: Jun 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00209300, this PHASE3 trial focuses on Ulcerative Colitis and remains completed. Sponsored by Ferring Pharmaceuticals, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ferring Pharmaceuticals

Data source: Ferring Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Augsburg, Germany , Beeskow, Germany , Berlin, Germany , Bochum, Germany , Bonn, Germany , Brussels, Belgium , Cologne, Germany , Copenhagen S, Denmark , Dachau, Germany and 48 more locations